Ozempic 2 MG/dose (8 MG/3 ML) 3ML
Ended Awarded
- Contract number
- SPE2DB25FW2XN
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,523
Award facts
- Contract value 100% obligated
- $15,522.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $15,522.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. Ozempic is a widely used medication for diabetes management, and its inclusion in this federal procurement reflects the pharmaceutical supply needs of military and veteran healthcare systems.
This delivery order is part of AmerisourceBergen's $999,999,999.00 Pharmaceutical Prime Vendor IDC with DLA Troop Support Medical (contract number SPE2DX), which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen has demonstrated substantial federal contracting capability, supplying a broad range of brand-name and generic medications, vaccines, and medical devices to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The DLA is currently planning to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to continue serving as a critical supplier for federal medical procurement needs.
Quick answers
Who was awarded contract SPE2DB25FW2XN?
SPE2DB25FW2XN was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 28, 2025.
How much is contract SPE2DB25FW2XN worth?
The government has obligated $15,523 on SPE2DB25FW2XN.
Is contract SPE2DB25FW2XN an order under another contract?
Yes. SPE2DB25FW2XN is a delivery order under SPE2DB22D2006, an indefinite delivery contract.
Was contract SPE2DB25FW2XN competed?
The extent of competition for SPE2DB25FW2XN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award